ArticleThe Journal of investigative dermatology2019
Drug Repurposing Prediction for Immune-Mediated Cutaneous Diseases using a Word-Embedding-Based Machine Learning Approach.
Article in The Journal of investigative dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- The role of machine learning in developing non-magnetic resonance imaging based biomarkers for multiple sclerosis: a systematic review.BMC medical informatics and decision making · 2022Pooled it
- Artificial intelligence in atopic dermatitis: Current applications and future perspectives.Chinese medical journal · 2026Review
- Artificial intelligence-enabled precision medicine for inflammatory skin diseases.The Journal of investigative dermatology · 2026Review
- From In Silico Hypothesis to Validation: The Role of Real-World Evidence in the Preliminary Verification of AI-Generated Drug-Repositioning Candidates: A Comprehensive Review.Journal of clinical medicine · 2026Review
- AΙ-Driven Drug Repurposing: Applications and Challenges.Medicines (Basel, Switzerland) · 2025Review
- Insights into the Impact of Artificial Intelligence on Psoriasis Treatment Strategies: A Mini Review.Indian dermatology online journal · 2025Article
- Electrostimulation: A Promising New Treatment for Psoriasis.International journal of molecular sciences · 2024Review
- Artificial Intelligence: A Snapshot of Its Application in Chronic Inflammatory and Autoimmune Skin Diseases.Life (Basel, Switzerland) · 2024Review
- CHAC1 as a novel biomarker for distinguishing alopecia from other dermatological diseases and determining its severity.IET systems biology · 2022Article
- Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs).Therapeutic advances in musculoskeletal disease · 2022Review
- Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles.Computational and structural biotechnology journal · 2022Article
- An introduction to machine learning and analysis of its use in rheumatic diseases.Nature reviews. Rheumatology · 2021Review
- A Study of the Recent Trends of Immunology: Key Challenges, Domains, Applications, Datasets, and Future Directions.Sensors (Basel, Switzerland) · 2021Review
- Advancement in predicting interactions between drugs used to treat psoriasis and its comorbidities by integrating molecular and clinical resources.Journal of the American Medical Informatics Association : JAMIA · 2021Article
- Machine learning for precision dermatology: Advances, opportunities, and outlook.Journal of the American Academy of Dermatology · 2021Review
- Exploration of databases and methods supporting drug repurposing: a comprehensive survey.Briefings in bioinformatics · 2021Review
- A computational workflow for the detection of candidate diagnostic biomarkers of Kawasaki disease using time-series gene expression data.Computational and structural biotechnology journal · 2021Article
- Machine Learning Applications in the Evaluation and Management of Psoriasis: A Systematic Review.Journal of psoriasis and psoriatic arthritis · 2020Article
- Machine Learning in Dermatology: Current Applications, Opportunities, and Limitations.Dermatology and therapy · 2020Review
- IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus.Science translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Immune-mediated diseases affect more than 20% of the population, and many autoimmune diseases affect the skin. Drug repurposing (or repositioning) is a cost-effective approach for finding drugs that can be used to treat diseases for which they are currently not prescribed. We implemented an efficient bioinformatics approach using word embedding to summarize drug information from more than 20 million articles and applied machine learning to model the drug-disease relationship. We trained our drug repurposing approach separately on nine cutaneous diseases (including psoriasis, atopic dermatitis, and alopecia areata) and eight other immune-mediated diseases and obtained a mean area under the receiver operating characteristic of 0.93 in cross-validation. Focusing in particular on psoriasis, a chronic inflammatory condition of skin that affects more than 100 million people worldwide, we were able to confirm drugs that are known to be effective for psoriasis and to identify potential candidates used to treat other diseases. Furthermore, the targets of drug candidates predicted by our approach were significantly enriched among genes differentially expressed in psoriatic lesional skin from a large-scale RNA sequencing cohort. Although our algorithm cannot be used to determine clinical efficacy, our work provides an approach for suggesting drugs for repurposing to immune-mediated cutaneous diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.